Nathalie Adda's most recent trade in Enanta Pharmaceuticals Inc was a trade of 42,260 Common Stock done at an average price of $71.3 . Disclosure was reported to the exchange on April 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.32 per share. | 01 Apr 2022 | 42,260 | 34,982 (0%) | 0% | 71.3 | 3,013,983 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 01 Apr 2022 | 31,664 | 82,646 (0%) | 0% | 30 | 949,920 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 31,664 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.71 per share. | 01 Apr 2022 | 18,076 | 47,191 (0%) | 0% | 71.7 | 1,296,230 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.35 per share. | 01 Apr 2022 | 16,875 | 67,767 (0%) | 0% | 63.3 | 1,069,031 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 16,875 | 13,125 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 16,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.42 per share. | 01 Apr 2022 | 16,000 | 50,982 (0%) | 0% | 31.4 | 502,720 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.57 per share. | 01 Apr 2022 | 9,625 | 50,892 (0%) | 0% | 43.6 | 419,361 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 9,625 | 21,175 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 73.42 per share. | 01 Apr 2022 | 9,009 | 34,982 (0%) | 0% | 73.4 | 661,441 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.75 per share. | 01 Apr 2022 | 8,299 | 77,242 (0%) | 0% | 70.7 | 587,154 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Apr 2022 | 6,285 | 41,267 (0%) | 0% | 48.5 | 304,948 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 6,285 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 01 Apr 2022 | 3,200 | 43,991 (0%) | 0% | 72.7 | 232,480 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Apr 2022 | 2,895 | 85,541 (0%) | 0% | 48.5 | 140,465 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 2,895 | 6,285 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.56 per share. | 01 Apr 2022 | 2,500 | 65,267 (0%) | 0% | 70.6 | 176,400 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 24,339 | 12,481 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 01 Mar 2022 | 24,339 | 59,321 (0%) | 0% | 43.5 | 1,057,773 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.26 per share. | 01 Mar 2022 | 24,239 | 35,082 (0%) | 0% | 70.3 | 1,703,032 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.07 per share. | 01 Mar 2022 | 12,481 | 34,982 (0%) | 0% | 70.1 | 874,544 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 12,481 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 01 Mar 2022 | 12,481 | 47,463 (0%) | 0% | 43.5 | 542,424 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.06 per share. | 01 Mar 2022 | 100 | 34,982 (0%) | 0% | 71.1 | 7,106 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 35,936 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 954 | 34,982 (0%) | 0% | 62.5 | 59,615 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 33,517 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.13 per share. | 11 Jan 2022 | 12,536 | 32,902 (0%) | 0% | 70.1 | 879,150 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 9,200 | 36,820 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 11 Jan 2022 | 9,200 | 42,102 (0%) | 0% | 43.5 | 399,832 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2022 | 3,336 | 31,664 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.00 per share. | 11 Jan 2022 | 3,336 | 45,438 (0%) | 0% | 30 | 100,080 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 33,744 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 9,547 | 13,953 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.52 per share. | 01 Nov 2021 | 9,547 | 36,491 (0%) | 0% | 48.5 | 463,220 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 85.02 per share. | 01 Nov 2021 | 7,495 | 27,044 (0%) | 0% | 85.0 | 637,225 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 84.31 per share. | 01 Nov 2021 | 1,952 | 34,539 (0%) | 0% | 84.3 | 164,573 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 86.21 per share. | 01 Nov 2021 | 100 | 26,944 (0%) | 0% | 86.2 | 8,621 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 08 Oct 2021 | 13,453 | 40,397 (0%) | 0% | 43.5 | 584,667 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.09 per share. | 08 Oct 2021 | 13,453 | 26,944 (0%) | 0% | 70.1 | 942,934 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 13,453 | 58,817 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 4,047 | 54,770 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.46 per share. | 08 Oct 2021 | 4,047 | 30,991 (0%) | 0% | 43.5 | 175,883 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.34 per share. | 08 Oct 2021 | 4,047 | 26,944 (0%) | 0% | 70.3 | 284,685 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 28,484 (0%) | 0% | - | Common Stock | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 5,250 | 0 | - | - | Restricted Stock Units | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 1,540 | 26,944 (0%) | 0% | 42.5 | 65,481 | Common Stock |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Nathalie Adda | Sr. VP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 23,234 (0%) | 0% | 0 | Common Stock |